Navigation Links
Cystic Fibrosis Market Sales to Grow $5.3 Billion with 28.96% CAGR to 2018 Says a New Report Available at

Dallas, TX (PRWEB) July 16, 2014

Researcher estimates the 2012 sales for Cystic Fibrosis to be approximately $1.2 billion across the six markets covered in this forecast: the US, France, Germany, Italy, Spain and the UK. By the end of the forecast period, sales will grow to approximately $5.3 billion, with a CAGR of 28.96%. The majority of sales will come from the US, which will represent 60% of the market by 2018.

Key Findings

  •     Rapid growth in the CF market is expected from 2012 to 2018.
  •     Emerging market players are employing diverse R&D strategies to gain entry in the CF market.
  •     A curative therapy is the most pressing unmet need in CF.
  •     Significant opportunities exist for novel disease modifying drugs.

Complete Report Available @ .

Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III clinical trial data for lumacaftor in combination with Kalydeco in patients with CF who have two copies of the F508del mutation. This novel combination therapy of CFTR modulators has the potential to treat the underlying cause of the disease for approximately 50% of all CF patients and drive rapid growth in the CF market.

Key Questions Answered

  •     What are the pressing unmet needs and remaining opportunities in the CF market?
  •     What R&D strategies are drug developers pursuing in the CF therapeutics space?
  •     What is the significance of CFTR modulators in the CF market?
  •     What is the clinical and commercial positioning of key pipeline products in the CF market?
  •     What are the innovative early-stage treatment approaches in the CF market?

Order a purchase copy of this report @


  •     Overview of CF, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
  •     Annualized CF therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018.
  •     Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the CF therapeutics market.
  •     Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including inhaled antibiotics, CFTR modulators and pancreatic enzyme products.
  •     Analysis of the current and future market competition in the US and five major EU CF therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Request a sample copy @

Reasons to buy

  •     Identify the unmet needs and remaining opportunities in the CF therapeutics market.
  •     Develop business strategies by understanding the trends shaping and driving the US and five major EU CF therapeutics market.
  •     Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  •     Assess the clinical and commercial viability of promising pipeline products.
  •     Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
  •     Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
  •     Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  •     Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU CF therapeutics market in future.

Table of Contents
1 Table of Contents
2 Introduction
3 Disease Overview
4 Epidemiology
5 Current Treatment Options
6 Unmet Needs Assessment and Oppportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
10 Appendix

Explore more reports on Pharmaceuticals industry at

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study evaluates use of inhaled saline for young children with cystic fibrosis
2. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
3. Cystic fibrosis patients of low SES are less likely to be accepted for lung transplant
4. Cystic kidney growth curbed
5. Impaired blood vessel function found in cystic fibrosis patients
6. Scientists identify new strategy to fight deadly infection in cystic fibrosis
7. Polycystic ovary syndrome puts glucose control in double jeopardy
8. Tiny RNA molecule may have role in polycystic ovary syndrome, insulin resistance
9. PCOS Diva Launches Spring Meal Plans For Women With Polycystic Ovarian Syndrome
10. New approaches in treating complicated childhood polycystic kidney disease
11. Fosamax Lawsuits Update: Rottenstein Law Group LLP Responds to Fosamax Cystic Fibrosis Study
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his ... is one of Joplin's most famous and beautiful concert posters. The concert was held ... Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom ...
(Date:11/26/2015)... Cambridge, ON (PRWEB) , ... November 26, 2015 ... ... availability of a real-time eReferral system for diagnostic imaging in the Waterloo region. ... mammography, BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) ...
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology: